| Bioactivity | Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma[1]. |
| Invitro | Enfortumab vedotin-ejfv is a fully human IgG1-kappa antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable maleimidocaproyl valine-citrulline linker (SGD-1006)[2]. |
| Name | Enfortumab vedotin-ejfv |
| CAS | 1346452-25-2 |
| Appearance | Solid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021 Jun;55(6):772-782. [2]. Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Feb 15;27(4):922-927. |